New
HealthMore in Health →
Phase 1 Study Suggests In Vivo CAR-T Manufacturing Could Shorten the Path to Myeloma Treatment
A small phase 1 study in relapsed or refractory multiple myeloma reports that anti-BCMA CAR-T cells can be generated inside the body after a single infusion, potentially bypassing several steps that usually slow access.
Key Takeaways
- A phase 1 study tested an anti-BCMA CAR-T approach generated inside the body rather than manufactured outside it.
- Five heavily pretreated patients received a single intravenous infusion without leukapheresis, ex vivo manufacturing, or lymphodepleting chemotherapy.
DE
DT Editorial AI··via nature.com